Literature DB >> 15197162

Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

Nicole Soranzo1, Gianpiero L Cavalleri, Michael E Weale, Nicholas W Wood, Chantal Depondt, Richard Marguerie, Sanjay M Sisodiya, David B Goldstein.   

Abstract

The difficulty of fine localizing the polymorphisms responsible for genotype-phenotype correlations is emerging as an important constraint in the implementation and interpretation of genetic association studies, and calls for the definition of protocols for the follow-up of associated variants. One recent example is the 3435C>T polymorphism in the multidrug transporter gene ABCB1, associated with protein expression and activity, and with several clinical conditions. Available data suggest that 3435C>T may not directly cause altered transport activity, but may be associated with one or more causal variants in the poorly characterized stretch of linkage disequilibrium (LD) surrounding it. Here we describe a strategy for the follow-up of reported associations, including a Bayesian formalization of the associated interval concept previously described by Goldstein. We focus on the region of high LD around 3435C>T to compile an exhaustive list of variants by (1) using a relatively coarse set of marker typings to assess the pattern of LD, and (2) resequencing derived and ancestral chromosomes at 3435C>T through the associated interval. We identified three intronic sites that are strongly associated with the 3435C>T polymorphism. One of them is associated with multidrug resistance in patients with epilepsy (chi2 = 3.78, P = 0.052), and sits within a stretch of significant evolutionary conservation. We argue that these variants represent additional candidates for influencing multidrug resistance due to P-glycoprotein activity, with the IVS 26+80 T>C being the best candidate among the three intronic sites. Finally, we describe a set of six haplotype tagging single-nucleotide polymorphisms that represent common ABCB1 variation surrounding 3435C>T in Europeans. Copyright 2004 Cold Spring Harbor Laboratory Press ISSN

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197162      PMCID: PMC442149          DOI: 10.1101/gr.1965304

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  41 in total

Review 1.  The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  A H Schinkel
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

2.  Pharmacogenetics in the laboratory and the clinic.

Authors:  David B Goldstein
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

3.  P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

Authors:  H Spahn-Langguth; G Baktir; A Radschuweit; A Okyar; B Terhaag; P Ader; A Hanafy; P Langguth
Journal:  Int J Clin Pharmacol Ther       Date:  1998-01       Impact factor: 1.366

4.  Phylogenetic shadowing of primate sequences to find functional regions of the human genome.

Authors:  Dario Boffelli; Jon McAuliffe; Dmitriy Ovcharenko; Keith D Lewis; Ivan Ovcharenko; Lior Pachter; Edward M Rubin
Journal:  Science       Date:  2003-02-28       Impact factor: 47.728

5.  MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes.

Authors:  Kersti Oselin; Thomas Gerloff; Przemyslaw M Mrozikiewicz; Rein Pähkla; Ivar Roots
Journal:  Fundam Clin Pharmacol       Date:  2003-08       Impact factor: 2.748

Review 6.  Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

Authors:  Alex Sparreboom; Romano Danesi; Yuichi Ando; Juliana Chan; William D Figg
Journal:  Drug Resist Updat       Date:  2003-04       Impact factor: 18.500

7.  Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1).

Authors:  S Ito; G Koren; P A Harper; M Silverman
Journal:  Can J Physiol Pharmacol       Date:  1993-01       Impact factor: 2.273

8.  Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein.

Authors:  R Truant; H Xiao; C J Ingles; J Greenblatt
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

9.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.

Authors:  I A de Lannoy; M Silverman
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

Review 10.  Transcriptional regulators of the human multidrug resistance 1 gene: recent views.

Authors:  Stéphane Labialle; Landry Gayet; Eric Marthinet; Dominique Rigal; Loris G Baggetto
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

View more
  25 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Genetics of drug resistance in epilepsy.

Authors:  Sanjay M Sisodiya
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 3.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

4.  Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression.

Authors:  Gabriela Bleiber; Margaret May; Raquel Martinez; Pascal Meylan; Jürg Ott; Jacques S Beckmann; Amalio Telenti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.

Authors:  Anna Wasilewska; Grzegorz Zalewski; Lech Chyczewski; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2006-10-17       Impact factor: 3.714

6.  Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

Authors:  Sarah K Tate; Chantal Depondt; Sanjay M Sisodiya; Gianpiero L Cavalleri; Stephanie Schorge; Nicole Soranzo; Maria Thom; Arjune Sen; Simon D Shorvon; Josemir W Sander; Nicholas W Wood; David B Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

7.  Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis.

Authors:  Wei-Ping Lv; Ren-Feng Han; Zhi-Rong Shu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 8.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

9.  Linkage and association analysis of CACNG3 in childhood absence epilepsy.

Authors:  Kate V Everett; Barry Chioza; Jean Aicardi; Harald Aschauer; Oebele Brouwer; Petra Callenbach; Athanasios Covanis; Olivier Dulac; Orvar Eeg-Olofsson; Martha Feucht; Mogens Friis; Françoise Goutieres; Renzo Guerrini; Armin Heils; Marianne Kjeldsen; Anna-Elina Lehesjoki; Andrew Makoff; Rima Nabbout; Ingrid Olsson; Thomas Sander; Auli Sirén; Paul McKeigue; Robert Robinson; Nichole Taske; Michele Rees; Mark Gardiner
Journal:  Eur J Hum Genet       Date:  2007-01-31       Impact factor: 4.246

Review 10.  Population genetic approaches to neurological disease: Parkinson's disease as an example.

Authors:  S Gandhi; P M Abou-Sleiman; D G Healy; M Weale; W Gilks; K Ahmadi; D B Goldstein; N W Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.